Key result
Liraglutide boosts long-term >=5% weight loss achievement by ~78% in adults with obesity.
Why the study?
Does liraglutide improve body weight and clinical outcomes in adults living with obesity?
Systematic Review (n=9,937)
Yes
Does liraglutide improve body weight and clinical outcomes in adults living with obesity?
Answers are grounded in this paper and cite their sources.
Liraglutide promotes clinically meaningful weight loss in adults with obesity, but is associated with an increased risk of adverse events and has uncertain effects on MACE and mortality.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Meza et al. (2025) conducted a systematic review in obesity (n=9,937). Liraglutide vs. placebo, no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs was evaluated on achieving 5% weight reduction (long-term: 104 to 162 weeks) (RR 1.78, 95% CI 1.51-2.09). Liraglutide likely increases the proportion of adults with obesity achieving at least 5% weight reduction at long-term follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: